Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
A director at Zealand Pharma As sold 10,000 shares at 138.110DKK and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of b...
>Q1 2019 results - Zealand Pharma yesterday afternoon reported its financial results for Q1 2019. No sales recorded over the period (after the sale of the rights for Soliqua and Lyxumia to Royalty Pharma last September), the operating loss widened to DKK 136m (vs -DKK 88m in Q1 2018) underscoring the decline in revenues and the rise in opex (R&D +36% to DKK 121m; +80% SG&A to DKK 14.5m) which reflects the progress of the development of the various molecules in its pip...
Maisons du Monde has reassured on its ability to continue generating strong sales growth over coming years. The group intends to generate c. EUR900m in additional sales by 2024 to ensure a 10.3%e sales CAGR. Whereas we expect no in-store B2C LfL growth, especially in France, the majority of growth (c.84%e) is set to stem from four levers: 1/ store openings in RoEurope, 2/ the US, 3/ e-commerce, 4/ B2B.
CARBIOS - CORPORATE | EUR15.5(+107%) Launch of a capital increase EUR13m capital increase by accelerated bookbuilding Industrial and commercial deployment expected as of 2023 Carbios’ technology fits into the circular economy of recycling
NOVARTIS - BUY | CHF96(+5%) An easy guidance for 2019 and a rich newsflow ahead Strong confidence in Cosentyx achieving USD5-6bn at peak The MS franchise is a major swing factor in 2019 A dense newsflow by year-end The guidance for 2019 looks conservative
NOVO NORDISK - | Without any new data, Novo-Nordisk leaves ADA 2019 stronger Oral semaglutide increasingly looks like new SoC Our biggest concern remains competition for Ozempic Lilly’s tirzepatide less of a threat than initially thought? Conclusion
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.